

Clovis Oncology, Inc.  
Form 8-K  
June 03, 2013

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **June 3, 2013**

**Clovis Oncology, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**                                  **001-35347**     **90-0475355**  
(State or other jurisdiction   (Commission   (I.R.S. Employer  
of incorporation)                      File Number) Identification No.)  
**2525 28<sup>th</sup> Street, Suite 100**

**Boulder, Colorado**                        **80301**  
(Address of principal  
executive offices)                                  (Zip Code)

Registrant's telephone number, including area code: **(303) 625-5000**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

---



**Item 8.01 Other Events**

On June 3, 2013, Clovis Oncology, Inc. issued a press release announcing initial findings from an ongoing Phase I/II monotherapy study of rucaparib, the company's oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of ovarian cancer. Initial results from the Phase I dose-escalation portion of this Phase I/II study are being presented for the first time today at a poster session during the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago.

A copy of the press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

Number and Description

99.1 Press Release, dated June 3, 2013.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CLOVIS ONCOLOGY, INC.**

June 3, 2013    By:    /s/ Erle T. Mast  
                               Name: Erle T. Mast  
                               Title: Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release, dated June 3, 2013.